Recent regulatory approvals and clinical advancements are shaping ophthalmic care. Lenz Therapeutics received FDA clearance to launch aceclidine-based eye drops addressing presbyopia, entering a challenging market for biopharmaceutical innovations in vision correction. Additionally, 4D Molecular Therapeutics reported that its gene therapy candidate for diabetic macular edema reduces the frequency of required injections, suggesting potential improvements in patient compliance and outcomes. Collaborations and partnerships in ocular health continue to grow, delivering innovative modalities across diagnostic and therapeutic domains.